Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, spoke on the design of the 2 phase 4 real-world studies investigating severity and quality of life impact of tildrakizumab for the treatment of psoriasis.
Tildrakizumab use was investigated in community practice patients with moderate to severe psoriasis to capture the real-world efficacy implications that are not derived from clinical trials, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Rozzo served as co-author of 2 studies presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting titled, “Real-world Effectiveness and Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Week 28 Interim Analysis of a Phase 4 Study,” and “A Phase 4, Real-World study of Tildrakizumab in Moderate-to-Severe Psoriasis: Week 28 Interim Analysis.”
Transcript
Two phase 4 real-world studies presented at AAD 2022 investigated tildrakizumab for the treatment of moderate to severe psoriasis. What insights can be gleaned from real-world use metrics on severity and quality of life?
In one of the presentations, we looked at the clinical efficacy and safety and then the other we looked at quality of life, which is very impaired in patients with moderate to severe psoriasis. The design was intended to capture moderate to severe patients in real-world practice, which are not necessarily the same as in clinical trials. These are patients that had at least 3% body surface area affected, moderate to severe disease in the eyes of the clinicians or the investigators in the trial, and who are candidates for phototherapy or systemic therapy.
Some of those aspects are similar to the trials, but some are not. And dermatologists often say clinical trial patients are not the patients they choose, because they're selected patients who are not particularly vulnerable to adverse events and well-defined populations because it's research.
The exciting part about this study is that they were true community practice patients. And the interesting part was that as these patients were followed for 28 weeks, we have results at AAD that are very exciting, very closely match those in the trials. And usually [in] real world studies, they don't. So, that's very gratifying, and it's very exciting for patients and for clinicians to see that.
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More